Articles > Insulins & Non-insulins

Executives of the Big Three pharma companies involved in diabetes research, development, and manufacturing — Eli Lilly and Co., Novo Nordisk, and Sanofi — spoke publicly this week at JPMorgan’s 2020 Healthcare conference on issues related to insulin pricing and supply.

Fiasp fast acting insulin pen

The U.S. Food and Drug Administration has approved Novo Nordisk's fast-acting Fiasp insulin for use in children as well as adults, the pharmaceutical firm announced Monday.

A patient loads insulin for his routine shot.

At least 17 states have passed laws carving out exceptions for pharmacists to fill insulin prescriptions during emergency situations. These legal reforms are seen by some advocates as the first real sign of progress for improved access to insulin in the United States.

logo for French pharma manufacturer Sanofi

Sanofi, the French pharmaceutical giant which manufactures the long-acting insulin Lantus, announced Monday that it would no longer be investing in research for new drugs to treat diabetes. The manufacturer also told investors it would no longer be investigating new treatments for cardiovascular health. “To be out of cardiovascular and diabetes is not easy for …

Insulin Singled Out in Ambitious Bill By House Democrats to Lower Drug Prices

The bill would mandate that the government negotiate with drug makers about the price of insulin, both in the Medicare program and for the open insurance market. It also includes many other mechanisms intended to lower the price of insulin and other drugs.

Children with High Genetic Risk for Type 1 Diabetes Have Distinct Gut Microbiomes When Compared to Those at Lower Risk

An examination of 403 biological samples reveals that some gut bacteria was absent in children at higher risk of developing type 1 diabetes.

Eylea, a Treatment for Diabetic Retinopathy, Now Available in Prefilled Syringes

The drug is just one of two on the market currently approved specifically to treat the diabetes-related eye condition, among other eye ailments.

ere are Six Recent Moves to Curb Co-Pay Costs for Insulin

Four insurers have introduced a cap on monthly insulin costs, but the federal government’s move to change regulations around high-deductible insurance plans may have the biggest long-term impact.

The company also will offer a $99 monthly subscription for up to three vials or two packs of any combination of Novo Nordisk’s analog insulins.

JDRF Announces the Creation of its First Center for Excellence

The inaugural Northern California Center for Excellence will bring together key diabetes researchers investigators involved in diabetes cellular therapy and immune system research from Stanford University and UCSF.